lobbying_activities: 3138838

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id filing_uuid filing_type registrant_name registrant_id client_name filing_year filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
3138838 0ec132e9-6c56-4e05-aa40-ef4a0ab5cb29 Q1 ARDELYX, INC. 401105832 ARDELYX, INC. 2024 first_quarter HCR H.R.5074 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 - To delay incorporation of oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual into the End-Stage Renal Disease (ESRD) Prospective Payment System. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   530000 0 0 2024-04-02T08:42:57-04:00